PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 4, 2015, Pages 280-287

  Wang, Min ^a   Ma, Haifen ^a   Pan, Yunbao ^b,c   Xiao, Weihua ^a   Li, Junqiang ^a   Yu, Jihong ^a   He, Ji ^a  

^a Ningbo Beilun people Hospital   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

biomarker; immunohistochemistry; ovarian tumors; PAX2; PAX8

Indexed keywords

TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PAX8; PAIRED BOX TRANSCRIPTION FACTOR; PAX2 PROTEIN, HUMAN; PAX8 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; COLLOID CARCINOMA; CONTROLLED STUDY; CYSTADENOMA; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN MUCINOUS TUMOR; OVARIAN SEROUS TUMOR; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; METABOLISM; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; BIOMARKERS, TUMOR; FEMALE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PAIRED BOX TRANSCRIPTION FACTORS; PAX2 TRANSCRIPTION FACTOR;

EID: 84928650803     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000065     Document Type: Article

References (32)

1. Zhuang H, Gao J, Hu Z, et al. Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013;8:e68994.
2. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203-211.
3. Mansouri A, Hallonet M, Gruss P. Pax genes and their roles in cell differentiation and development. Curr Opin Cell Biol. 1996;8:851-857.
4. Dahl E, Koseki H, Balling R. Pax genes and organogenesis. Bioessays. 1997;19:755-765.
5. Bouchard M, Souabni A, Mandler M, et al. Nephric lineage specification by Pax2 and Pax8. Genes Dev. 2002;16:2958-2970.
6. Grote D, Souabni A, Busslinger M, et al. Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development. 2006;133: 53-61.
7. Narlis M, Grote D, Gaitan Y, et al. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol. 2007;18:1121-1129.
8. Dressler GR. The specification and maintenance of renal cell types by epigenetic factors. Organogenesis. 2009;5:73-82.
9. Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol. 2009;33:376-383.
10. Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol. 2007;20:856-863.
11. Tung CS, Mok SC, Tsang YT, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009;22:1243-1250.
12. Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J. 1993;12:2361-2367.
13. Ozcan A, Zhai J, Hamilton C, et al. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol. 2009;131:393-404.
14. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-1227.
15. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010;17:377-393.
16. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92-109.
17. McKnight R, Cohen C, Siddiqui MT. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma. Cancer Cytopathol. 2010;118:298-302.
18. Tong GX, Devaraj K, Hamele-Bena D, et al. Pax8: a marker for carcinoma of Mullerian origin in serous effusions. Diagn Cytopathol. 2011;39:567-574.
19. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol. 2011;39: 651-656.
20. Song H, Kwan SY, Izaguirre DI, et al. PAX2 expression in ovarian cancer. Int J Mol Sci. 2013;14:6090-6105.
21. Liliac L, Carcangiu ML, Canevari S, et al. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. Rom J Morphol Embryol. 2013;54:17-27.
22. Mhawech-Fauceglia P, Wang D, Menesses T, et al. Pax-8 is a reliable marker in making the diagnosis in advanced stage epithelial ovarian carcinoma and primary peritoneal carcinoma for neoadjuvant chemotherapy on cell block and biopsy specimens. Histopathology. 2012;60:1019-1020.
23. Sharma SG, Gokden M, McKenney JK, et al. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol. 2010;18:494-498.
24. Pan Y, Zhang Q, Tian L, et al. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012;72:1890-1900.
25. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893-1907.
26. Nagele F, Petru E, Medl M, et al. Preoperative CA125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995;86:259-264.
27. Eltabbakh GH, Yadav PR, Morgan A. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol. 1999;75:476-479.
28. Gao FF, Krasinskas AM, Chivukula M. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of Mullerian origin? Appl Immunohistochem Mol Morphol. 2012;20:272-276.
29. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14:4376-4386.
30. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337.
31. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.
32. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293-299.